Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.
A 3-variable score that encompasses dyspnea score, prednisone use, and prior hospitalization for COPD exacerbations can predict mortality and readmission risk.